智飞生物（300122）8月13日主力资金净流入6656.09万元

Group 1 - The core viewpoint of the news is that Chongqing Zhifei Biological Products Co., Ltd. has experienced a significant decline in revenue and profit in the latest quarterly report, indicating potential challenges for the company moving forward [1][3] - As of August 13, 2025, the company's stock price closed at 23.72 yuan, with a 1.89% increase and a trading volume of 553,700 hands, amounting to 1.308 billion yuan in transaction value [1] - The net inflow of main funds today was 66.56 million yuan, accounting for 5.09% of the transaction amount, with large orders contributing significantly to this inflow [1] Group 2 - For the first quarter of 2025, the company reported total operating revenue of 2.374 billion yuan, a year-on-year decrease of 79.16%, and a net profit attributable to shareholders of 305.14 million yuan, down 120.93% year-on-year [1] - The company has a current ratio of 2.298, a quick ratio of 1.029, and a debt-to-asset ratio of 36.85%, indicating its liquidity and financial stability [1] - Chongqing Zhifei Biological has made investments in 9 companies, participated in 1,170 bidding projects, and holds 34 trademarks and 81 patents, along with 63 administrative licenses [2]